(Korean) 이노엔, 보로노이서 ‘선택적 RET 저해제’ 도입…항암신약 개발 – 한국경제 BIO Insight
admin2021-11-09T10:17:05+00:00Sorry, this entry is only available in Korean.
JW Pharmaceutical·VORONOI, Joint develpoment of targeting STAT3 in anticancer field
voronoiio2021-11-09T10:00:40+00:00JW Pharmaceutical·VORONOI, Joint develpoment of targeting STAT3 in anticancer field - mk.co.kr On December 2, JW Pharmaceutical inked a deal with Korean biotech startup Voronoi to develop next-generation innovative new drugs. It plans to develop a next-generation innovative new drug with global competitiveness by combining JW Pharmaceutical's small molecule anticancer drug candidate of targeting STAT3 with Voronoi's protein decomposition technology 'Protein Degrader(PROTAC; Proteolysis-targeting chimera)'. 기사 전문보기
(Korean) 보로노이, 美제약사에 폐암 치료제 7200억 기술수출
voronoiio2021-10-28T14:20:34+00:00Sorry, this entry is only available in Korean.
Dana-Farber Cancer Institute visits VORONOI…”Strengthening partnerships by strengthening joint research, etc.”
admin2021-11-09T10:19:19+00:00Sorry, this entry is only available in Korean.
Dana-Farber Cancer Institute grants exclusive right of protein degradation patent to Voronoi – Asia Biz
admin2019-12-30T18:22:31+00:00Dana-Farber Cancer Institute grants exclusive right of protein degradation patent to Voronoi-AsiaBiz View the update
Nathanael Gray and Eric Fischer along with Deerfield Management create new Center for Protein Degradation at DFCI
voronoiio2019-07-04T18:21:55+00:00Dana-Farber Cancer Institute and Deerfield Management announced today an up to $80 million collaboration to create the Center for Protein Degradation at Dana-Farber to be led by BCMP Faculty members, Nathanael Gray and Eric Fischer,.
Voronoi’s NSCLC program gains lots of excitement from AACR
Link-home2021-01-27T09:21:53+00:00미국 암학회 대표, 한국 벤처 극찬..폐암 치료제 호평 - 헤럴드경제 암학회(AACR) 대표 마가렛 포티 박사 트위터로 한국기업 보로노이 발표 올리며 "큰 관심 쏟아져" "복수의 글로벌사와 기술수출 협의 중" 대박 기대감 기사 전문보기
